Tamoxifen induced-non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist.
Ahmed
M H
MH
Osman
K A
KA
D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D001629:Bezafibrate / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000150:complications / Q000473:pathology*; D048909:Diabetes Complications; D018450:Disease Progression; D005234:Fatty Liver / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D011379:Prognosis; D013629:Tamoxifen / Q000009:adverse effects*; D013997:Time Factors
D018931:Antineoplastic Agents, Hormonal; D000960:Hypolipidemic Agents; D013629:Tamoxifen; D001629:Bezafibrate